RKLB Fundamental Analysis - ROCKET LAB CORP

Fundamental Rating

RKLB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 71 industry peers in the Aerospace & Defense industry. RKLB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RKLB shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

RKLB had negative earnings in the past year.

In the past year RKLB has reported a negative cash flow from operations.

In the past 5 years RKLB always reported negative net income.

In the past 5 years RKLB always reported negative operating cash flow.

1.2 Ratios

RKLB's Return On Assets of -8.90% is on the low side compared to the rest of the industry. RKLB is outperformed by 71.83% of its industry peers.

RKLB has a Return On Equity of -15.43%. This is in the lower half of the industry: RKLB underperforms 67.61% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.9%
ROE	-15.43%
ROIC	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RKLB's Gross Margin of 31.70% is fine compared to the rest of the industry. RKLB outperforms 69.01% of its industry peers.

RKLB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	31.7%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, RKLB has more shares outstanding

RKLB has more shares outstanding than it did 5 years ago.

The debt/assets ratio for RKLB is higher compared to a year ago.

2.2 Solvency

RKLB has an Altman-Z score of 23.87. This indicates that RKLB is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 23.87, RKLB belongs to the top of the industry, outperforming 97.18% of the companies in the same industry.

RKLB has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.

RKLB has a Debt to Equity ratio of 0.32. This is in the better half of the industry: RKLB outperforms 63.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Altman-Z	23.87

ROIC/WACCN/A

WACC10.01%

2.3 Liquidity

RKLB has a Current Ratio of 3.18. This indicates that RKLB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of RKLB (3.18) is better than 60.56% of its industry peers.

RKLB has a Quick Ratio of 2.83. This indicates that RKLB is financially healthy and has no problem in meeting its short term obligations.

RKLB's Quick ratio of 2.83 is fine compared to the rest of the industry. RKLB outperforms 76.06% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.18
Quick Ratio	2.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for RKLB have decreased by -2.70% in the last year.

RKLB shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.42%.

Measured over the past years, RKLB shows a very strong growth in Revenue. The Revenue has been growing by 55.23% on average per year.

EPS 1Y (TTM)-2.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70%

Revenue 1Y (TTM)52.42%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

3.2 Future

RKLB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.40% yearly.

The Revenue is expected to grow by 33.45% on average over the next years. This is a very strong growth

EPS Next Y-4%

EPS Next 2Y15.71%

EPS Next 3Y31.27%

EPS Next 5Y32.4%

Revenue Next Year38.04%

Revenue Next 2Y43.14%

Revenue Next 3Y40.97%

Revenue Next 5Y33.45%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RKLB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year RKLB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RKLB's earnings are expected to grow with 31.27% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.71%

EPS Next 3Y31.27%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

RKLB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET LAB CORP

NASDAQ:RKLB (12/29/2025, 6:40:39 PM)

After market: 70.15 +0.03 (+0.04%)

70.12

-0.53 (-0.75%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)11-10 2025-11-10/amc

Earnings (Next)N/A N/A

Inst Owners57.97%

Inst Owner Change0.99%

Ins Owners0.75%

Ins Owner Change6.74%

Market Cap37.46B

Revenue(TTM)554.53M

Net Income(TTM)-197.63M

Analysts80

Price Target66.47 (-5.21%)

Short Float %8.62%

Short Ratio2.11

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)30.22%

Min EPS beat(2)-11.38%

Max EPS beat(2)71.81%

EPS beat(4)3

Avg EPS beat(4)18.1%

Min EPS beat(4)-11.38%

Max EPS beat(4)71.81%

EPS beat(8)7

Avg EPS beat(8)15.56%

EPS beat(12)8

Avg EPS beat(12)9.83%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)2.41%

Min Revenue beat(2)0.19%

Max Revenue beat(2)4.63%

Revenue beat(4)2

Avg Revenue beat(4)0.8%

Min Revenue beat(4)-0.99%

Max Revenue beat(4)4.63%

Revenue beat(8)3

Avg Revenue beat(8)-1.04%

Revenue beat(12)5

Avg Revenue beat(12)-0.57%

Revenue beat(16)8

Avg Revenue beat(16)0.96%

PT rev (1m)3.42%

PT rev (3m)42.57%

EPS NQ rev (1m)-0.18%

EPS NQ rev (3m)-20.21%

EPS NY rev (1m)13.3%

EPS NY rev (3m)13.05%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)4.99%

Revenue NY rev (1m)1.56%

Revenue NY rev (3m)2.16%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	67.54
P/FCF	N/A
P/OCF	N/A
P/B	29.24
P/tB	45.06
EV/EBITDA	N/A

EPS(TTM)-0.38

EYN/A

EPS(NY)-0.24

Fwd EYN/A

FCF(TTM)-0.43

FCFYN/A

OCF(TTM)-0.19

OCFYN/A

SpS1.04

BVpS2.4

TBVpS1.56

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.9%
ROE	-15.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	31.7%
FCFM	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.25

Health

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	334.43%
Cap/Sales	23.12%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.18
Quick Ratio	2.83
Altman-Z	23.87

F-Score5

WACC10.01%

ROIC/WACCN/A

Cap/Depr(3y)174.96%

Cap/Depr(5y)206.2%

Cap/Sales(3y)19.28%

Cap/Sales(5y)34.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-2.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70%

EPS Next Y-4%

EPS Next 2Y15.71%

EPS Next 3Y31.27%

EPS Next 5Y32.4%

Revenue 1Y (TTM)52.42%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

Revenue Next Year38.04%

Revenue Next 2Y43.14%

Revenue Next 3Y40.97%

Revenue Next 5Y33.45%

EBIT growth 1Y-23.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year41.8%

EBIT Next 3Y42.77%

EBIT Next 5Y36.07%

FCF growth 1Y-71.68%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-36.74%

OCF growth 3YN/A

OCF growth 5YN/A

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

ChartMill assigns a fundamental rating of 3 / 10 to RKLB.

Can you provide the valuation status for ROCKET LAB CORP?

ChartMill assigns a valuation rating of 1 / 10 to ROCKET LAB CORP (RKLB). This can be considered as Overvalued.

How profitable is ROCKET LAB CORP (RKLB) stock?

ROCKET LAB CORP (RKLB) has a profitability rating of 1 / 10.

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?

The Earnings per Share (EPS) of ROCKET LAB CORP (RKLB) is expected to decline by -4% in the next year.

ROCKET LAB CORP (RKLB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ROCKET LAB CORP / RKLB FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

Can you provide the valuation status for ROCKET LAB CORP?

How profitable is ROCKET LAB CORP (RKLB) stock?

What is the expected EPS growth for ROCKET LAB CORP (RKLB) stock?